Phase I trial of Staphylococcus aureus Cowan I immunoperfusion.
Staphylococcus aureus Cowan I has shown antitumor activity in in vitro and in animal tumor models. It is hypothesized that this antineoplastic effect results from the interaction of protein A on the cell surface of Cowan I strain S. aureus and immunosuppressive circulating immune complexes. Therefore, we treated five patients with ex vivo plasma immuno-perfusion over killed and fixed S. aureus Cowan I. Toxic effects were marked in all patients and appeared to be related to the plasma volume infused and rate of infusion. Toxic reactions occurred in the cardiovascular, respiratory, and hematopoietic systems. No responses even minimal or transient, were observed in this phase I trial. This toxicity may be reduced if the rate of plasma infusion decreases.
D000328:Adult; D000368:Aged; D005069:Evaluation Studies as Topic; D006801:Humans; D007167:Immunotherapy; D008875:Middle Aged; D009369:Neoplasms / Q000628:therapy*; D010477:Perfusion; D012119:Respiration; D013205:Staphylococcal Protein A / Q000627:therapeutic use*; D013997:Time Factors
D013205:Staphylococcal Protein A